drugset / Trial / NCT04283019
The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions
Phase 1
Completed
75 enrolled
Johns Hopkins University
Canopy Growth Corporation · collabSubstance Abuse And Mental Health Administration · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
Timeline
- Start
- 2021-08-15
- Primary completion
- 2024-06-17
- Completion
- 2024-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 100 mg | Oral |
| Subject | THC | Unknown | 2.8 mg | Oral |
| Subject | THC | Unknown | 3.7 mg | Oral |
Indications
No indication recorded.